{"id":"https://openalex.org/W2942849386","doi":"https://doi.org/10.1186/s40425-019-0570-8","title":"The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation","display_name":"The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation","alternate_titles":[],"publication_year":2019,"publication_date":"2019-04-11","ids":{"openalex":"https://openalex.org/W2942849386","doi":"https://doi.org/10.1186/s40425-019-0570-8","mag":"2942849386","pmid":"https://pubmed.ncbi.nlm.nih.gov/30975201","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6458634"},"language":"en","primary_location":{"id":"doi:10.1186/s40425-019-0570-8","doi":"https://doi.org/10.1186/s40425-019-0570-8","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s40425-019-0570-8","pdf_url":"https://jitc.bmj.com/content/jitc/7/1/103.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2942849386"],"child_works_count":9,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/7/1/103.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006155460","display_name":"Anne M\u00e5nsson Kvarnhammar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Anne M\u00e5nsson Kvarnhammar","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden. amk@alligatorbioscience.com","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden. amk@alligatorbioscience.com","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072741407","display_name":"Niina Veitonm\u00e4ki","orcid":"https://orcid.org/0000-0001-6933-0823","observed_orcids":["https://orcid.org/0000-0001-6933-0823"]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Niina Veitonm\u00e4ki","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068228532","display_name":"Karin H\u00e4gerbrand","orcid":"https://orcid.org/0009-0004-5662-6990","observed_orcids":["https://orcid.org/0009-0004-5662-6990"]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karin H\u00e4gerbrand","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002749401","display_name":"Anna Dahlman","orcid":"https://orcid.org/0000-0002-5092-5752","observed_orcids":["https://orcid.org/0000-0002-5092-5752"]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anna Dahlman","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103020264","display_name":"Karin Enell Smith","orcid":"https://orcid.org/0009-0004-2117-2503","observed_orcids":["https://orcid.org/0009-0004-2117-2503"]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karin Enell Smith","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034448965","display_name":"Sara Fritzell","orcid":"https://orcid.org/0000-0003-1079-2614","observed_orcids":["https://orcid.org/0000-0003-1079-2614"]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sara Fritzell","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072019967","display_name":"Laura von Schantz","orcid":"https://orcid.org/0000-0003-1236-3135","observed_orcids":["https://orcid.org/0000-0003-1236-3135"]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Laura von Schantz","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028606030","display_name":"Mia Thagesson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mia Thagesson","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025033564","display_name":"Doreen Werchau","orcid":"https://orcid.org/0000-0002-6913-837X","observed_orcids":["https://orcid.org/0000-0002-6913-837X"]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Doreen Werchau","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003226508","display_name":"Kristine Smedenfors","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kristine Smedenfors","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081586079","display_name":"Maria Helena Johansson","orcid":"https://orcid.org/0000-0001-5700-1985","observed_orcids":["https://orcid.org/0000-0001-5700-1985"]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Maria Johansson","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Anna Ros\u00e9n","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anna Ros\u00e9n","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020125374","display_name":"Ida \u00c5berg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ida \u00c5berg","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087966966","display_name":"Magnus Winnerstam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Magnus Winnerstam","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010490668","display_name":"Eva Nyblom","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eva Nyblom","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052996445","display_name":"Karin Barchan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karin Barchan","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038303467","display_name":"Christina Furebring","orcid":"https://orcid.org/0000-0002-6680-1543","observed_orcids":["https://orcid.org/0000-0002-6680-1543"]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christina Furebring","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018953314","display_name":"Per Norl\u00e9n","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Per Norl\u00e9n","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001191544","display_name":"Peter Ellmark","orcid":"https://orcid.org/0000-0002-6687-1250","observed_orcids":["https://orcid.org/0000-0002-6687-1250"]},"institutions":[{"id":"https://openalex.org/I4210088933","display_name":"Medicon Village","ror":"https://ror.org/00a1grh69","country_code":"SE","type":"other","lineage":["https://openalex.org/I4210088933"]},{"id":"https://openalex.org/I4210130540","display_name":"Alligator Bioscience (Sweden)","ror":"https://ror.org/03h80hk08","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210130540"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Peter Ellmark","raw_affiliation_strings":["Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alligator Bioscience AB, Medicon Village, Scheelev\u00e4gen 2, 223 81, Lund, Sweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]},{"raw_affiliation_string":"grid.432080.dAlligator Bioscience AB\nMedicon Village, Scheelev\u00e4gen 2\n223 81\nLund\nSweden","institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5006155460"],"corresponding_institution_ids":["https://openalex.org/I4210088933","https://openalex.org/I4210130540"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":6.8542,"has_fulltext":true,"cited_by_count":127,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.98015676,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"7","issue":"1","first_page":"103","last_page":"103"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.9279999732971191},{"id":"https://openalex.org/keywords/ox40","display_name":"OX40","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.9959999918937683},{"id":"https://openalex.org/keywords/cd86","display_name":"CD86","score":0.6299999952316284},{"id":"https://openalex.org/keywords/treg-depletion","display_name":"Treg depletion","score":0.6150000095367432},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.8130000233650208},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.9200000166893005},{"id":"https://openalex.org/keywords/tumor-immunology","display_name":"tumor immunology","score":0.6859999895095825},{"id":"https://openalex.org/keywords/immunological-memory","display_name":"immunological memory","score":0.7580000162124634},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.5960000157356262},{"id":"https://openalex.org/keywords/bladder-cancer","display_name":"bladder cancer","score":0.765999972820282},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.9750000238418579},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.9430000185966492},{"id":"https://openalex.org/keywords/tumor-localization","display_name":"tumor localization","score":0.3149999976158142}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.6427761316299438},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6048293709754944},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.568867027759552},{"id":"https://openalex.org/C2781101188","wikidata":"https://www.wikidata.org/wiki/Q5009846","display_name":"CD86","level":4,"score":0.5602895617485046},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.520991861820221},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.47117048501968384},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.46929794549942017},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4629982113838196},{"id":"https://openalex.org/C2776662205","wikidata":"https://www.wikidata.org/wiki/Q2459684","display_name":"Tumor antigen","level":4,"score":0.4503454566001892},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.448581725358963},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.42343056201934814},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.39840325713157654}],"mesh":[{"descriptor_ui":"D000075082","descriptor_name":"Proof of Concept Study","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D003412","descriptor_name":"Cricetulus","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004354","descriptor_name":"Drug Screening Assays, Antitumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008822","descriptor_name":"Mice, Transgenic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016466","descriptor_name":"CHO Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":"Q000637","qualifier_name":"transplantation","is_major_topic":false},{"descriptor_ui":"D050378","descriptor_name":"T-Lymphocytes, Regulatory","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D050378","descriptor_name":"T-Lymphocytes, Regulatory","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053262","descriptor_name":"Receptors, OX40","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D053262","descriptor_name":"Receptors, OX40","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D053262","descriptor_name":"Receptors, OX40","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D057809","descriptor_name":"HEK293 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061251","descriptor_name":"Primary Cell Culture","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1186/s40425-019-0570-8","doi":"https://doi.org/10.1186/s40425-019-0570-8","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s40425-019-0570-8","pdf_url":"https://jitc.bmj.com/content/jitc/7/1/103.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6458634","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6458634/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Immunother Cancer","raw_type":"Text"},{"id":"pmid:30975201","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30975201","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for immunotherapy of cancer","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:ac146a36143540ed83d59ae4ac9773f4","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/ac146a36143540ed83d59ae4ac9773f4","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1186/s40425-019-0570-8","doi":"https://doi.org/10.1186/s40425-019-0570-8","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s40425-019-0570-8","pdf_url":"https://jitc.bmj.com/content/jitc/7/1/103.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2942849386.pdf","grobid_xml":"https://content.openalex.org/works/W2942849386.grobid-xml"},"referenced_works_count":50,"referenced_works":["https://openalex.org/W1423342398","https://openalex.org/W1838338895","https://openalex.org/W1914776013","https://openalex.org/W1981528932","https://openalex.org/W2019022043","https://openalex.org/W2031464151","https://openalex.org/W2033897823","https://openalex.org/W2042108941","https://openalex.org/W2057377546","https://openalex.org/W2057965214","https://openalex.org/W2064431192","https://openalex.org/W2100228832","https://openalex.org/W2101581360","https://openalex.org/W2105459360","https://openalex.org/W2121080857","https://openalex.org/W2122226789","https://openalex.org/W2128758225","https://openalex.org/W2131874142","https://openalex.org/W2133075384","https://openalex.org/W2149244682","https://openalex.org/W2155189639","https://openalex.org/W2168284316","https://openalex.org/W2201977796","https://openalex.org/W2337073303","https://openalex.org/W2398545566","https://openalex.org/W2408790673","https://openalex.org/W2516271598","https://openalex.org/W2528216460","https://openalex.org/W2570514524","https://openalex.org/W2572174216","https://openalex.org/W2588032129","https://openalex.org/W2619600619","https://openalex.org/W2753432434","https://openalex.org/W2774533844","https://openalex.org/W2790795290","https://openalex.org/W2791782653","https://openalex.org/W2792557198","https://openalex.org/W2795781326","https://openalex.org/W2799464107","https://openalex.org/W2799553179","https://openalex.org/W2804569878","https://openalex.org/W2807748927","https://openalex.org/W2808202038","https://openalex.org/W2883858361","https://openalex.org/W2887577080","https://openalex.org/W2888298425","https://openalex.org/W2894919607","https://openalex.org/W2903147538","https://openalex.org/W2907564726","https://openalex.org/W4253193856"],"related_works":["https://openalex.org/W2885653952"],"abstract_inverted_index":{"Background":[0],"The":[1,284],"CTLA-4":[2,17,54,66,89,237,264],"blocking":[3],"antibody":[4,72],"ipilimumab":[5],"has":[6,29,256,296],"demonstrated":[7,194],"substantial":[8],"and":[9,22,102,137,148,154,165,176,187,199,203,224,228,238,254,271,292],"durable":[10],"effects":[11],"in":[12,23,32,168,179],"patients":[13],"with":[14,25,57,132,171,267,281],"melanoma.":[15],"While":[16],"therapy,":[18],"both":[19],"as":[20],"monotherapy":[21],"combination":[24],"PD-1":[26,208],"targeting":[27,55,69,236,265],"therapies,":[28],"great":[30],"potential":[31,258],"many":[33],"indications,":[34],"the":[35,38,80,205,214,220,226,245,257],"toxicities":[36],"of":[37,79,84,99,222,230,290],"current":[39],"treatment":[40],"regimens":[41],"may":[42],"limit":[43],"their":[44],"use.":[45],"Thus,":[46],"there":[47],"is":[48,63,192,242,275],"a":[49,64,87,261,293],"medical":[50],"need":[51],"for":[52,144],"new":[53],"therapies":[56],"improved":[58,268],"benefit-risk":[59],"profile.":[60],"Methods":[61],"ATOR-1015":[62,161,172,196,211,241,274],"human":[65,85,115,127],"x":[67],"OX40":[68,94,128,239],"IgG1":[70],"bispecific":[71],"generated":[73],"by":[74],"linking":[75],"an":[76,92],"optimized":[77],"version":[78],"Ig-like":[81],"V-type":[82],"domain":[83],"CD86,":[86],"natural":[88],"ligand,":[90],"to":[91,207,213,244,259,278],"agonistic":[93],"antibody.":[95],"In":[96,120],"vitro":[97],"evaluation":[98],"T-cell":[100,151,163],"activation":[101,152,164,229],"T":[103,146,232],"regulatory":[104],"cell":[105,118,147],"(Treg)":[106],"depletion":[107,167],"was":[108],"performed":[109],"using":[110,126,157],"purified":[111],"cells":[112],"from":[113,139],"healthy":[114],"donors":[116],"or":[117],"lines.":[119],"vivo":[121],"anti-tumor":[122],"responses":[123],"were":[124,142],"studied":[125],"transgenic":[129],"(knock-in)":[130],"mice":[131,141],"established":[133],"syngeneic":[134,181],"tumors.":[135],"Tumors":[136],"spleens":[138],"treated":[140],"analyzed":[143],"CD8+":[145,231],"Treg":[149,166],"frequencies,":[150],"markers":[153],"tumor":[155,174,182,215,246],"localization":[156],"flow":[158],"cytometry.":[159],"Results":[160],"induces":[162,197,250],"vitro.":[169],"Treatment":[170],"reduces":[173,219],"growth":[175],"improves":[177],"survival":[178],"several":[180],"models,":[183],"including":[184],"bladder,":[185],"colon":[186],"pancreas":[188],"cancer":[189],"models.":[190],"It":[191],"further":[193],"that":[195],"tumor-specific":[198],"long-term":[200],"immunological":[201],"memory":[202],"enhances":[204],"response":[206],"inhibition.":[209],"Moreover,":[210],"localizes":[212],"area":[216,247],"where":[217,248],"it":[218,249],"frequency":[221],"Tregs":[223],"increases":[225],"number":[227],"cells.":[233],"Conclusions":[234],"By":[235],"simultaneously,":[240],"directed":[243],"enhanced":[251],"immune":[252],"activation,":[253],"thus":[255],"be":[260],"next":[262],"generation":[263],"therapy":[266],"clinical":[269,288],"efficacy":[270],"reduced":[272],"toxicity.":[273],"also":[276],"expected":[277],"act":[279],"synergistically":[280],"anti-PD-1/PD-L1":[282],"therapy.":[283],"pre-clinical":[285],"data":[286],"support":[287],"development":[289],"ATOR-1015,":[291],"first-in-human":[294],"trial":[295],"started":[297],"(NCT03782467).":[298]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2942849386","counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":10},{"year":2024,"cited_by_count":19},{"year":2023,"cited_by_count":21},{"year":2022,"cited_by_count":24},{"year":2021,"cited_by_count":23},{"year":2020,"cited_by_count":16},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2019-05-09T00:00:00"}
